Faricimab meets primary endpoints in phase 3 wet AMD studies

Faricimab met its primary endpoint in two phase 3 studies, with injections every 16 weeks achieving noninferior visual acuity outcomes compared aflibercept every 8 weeks in wet age-related macular degeneration, according to a press release.
In the TENAYA and LUCERNE studies, 45% of participants were dosed with faricimab (Genentech) every 16 weeks in the first year. Subjects achieved noninferior visual acuity outcomes compared with patients who received Eylea (aflibercept, Regeneron) injections every 8 weeks, the release said. In addition, faricimab presented no new or unexpected safety

Full Story →